# HCV IgM

Enzyme ImmunoAssay (ELISA) for the quantitative/qualitative determination of IgM antibodies to Hepatitis C Virus in human serum and plasma

- for "in vitro" diagnostic use only -



# **DIA.PRO**

Diagnostic Bioprobes Srl Via G. Carducci n° 27 20099 Sesto San Giovanni (Milano) - Italy

Phone +39 02 27007161 Fax +39 02 44386771 e-mail: info@diapro.it

> REF CVM.CE 96 Tests

Doc.: INS CVM.CE Page 2 of 8 Rev.: 2 Date: 2019/11

# **HCV IgM**

# A. INTENDED USE

Enzyme ImmunoAssay (ELISA) for the quantitative/qualitative determination of IgM antibodies to Hepatitis C Virus in human plasma and sera. The kit is mainly intended for the follow-up of HCV chronic patients submitted to anti-viral pharmaceutical treatment. For "in vitro" diagnostic use only.

#### **B. INTRODUCTION**

Antiviral drugs, such as Interferon taken alone or in combination with Ribavirin, can be used for the treatment of persons with chronic viral hepatitis C.

Treatment with interferon alone is effective in about 10% to 20% of patients. Interferon combined with Ribavirin is effective in about 30% to 50% of patients. Ribavirin does not appear to be effective when used alone.

Active production of HCV antigens in the liver of chronic patients generates spikes of IgM antibodies production and release of liver specific enzymes, similar to what happen in HBV chronic patients. The presence of anti viral IgM is usually correlated to a phase of sufferance and cellular damage of the liver.

During the pharmaceutical treatment HCV IgM may represent a marker for the follow-up of the efficiency of the drug itself, monitoring the balance between its effectiveness and the side effects, that often may be heavy for the patient.

#### C. PRINCIPLE OF THE TEST

Microplates are coated with HCV immunodominant synthetic antigens (core peptide, recombinant NS3, NS4 and NS5 peptides).

In the 1<sup>st</sup> incubation, the solid phase is treated with diluted samples and anti HCV IgM are captured, if present, by the antigens. After washing out all the other components of the sample, in the 2<sup>nd</sup> incubation bound anti-HCV IgM are detected by the addition of anti hIgM antibody, labeled with peroxidase (HRP). The enzyme captured on the solid phase, acting on the substrate/chromogen mixture, generates an optical signal that is proportional to the amount of anti-HCV IgM antibodies present in the sample.

The presence of IgM in the sample may therefore be quantitated by means of a calibration curve able to determine the content of the antibody in arbU/ml.

Neutralization of IgG anti-HCV, carried out directly in the well, is performed in the assay in order to block interferences due to this class of antibodies in the determination of IgM.

#### D. COMPONENTS

Each kit contains sufficient reagents to perform 96 tests.

# 1. Microplate: MICROPLATE

12 strips x 8 microwells coated with HCV-specific synthetic antigens (core, NS4 and NS5 peptides and recombinant NS3). Plates are sealed into a bag with desiccant.

# 2. Calibration Curve: CAL N° ...

6x2.0 ml/vial. Ready to use and color coded standard curve calibrated on an Internal Gold Standard (in absence of a defined international one) or IGS, ranging:

It contains chemical inactivated HCV IgM positive human plasma, 100 mM Tris buffer pH 7.4+/-0.1, 0.2% Tween 20, 0.09% sodium azide and 0.045% de ProClin 300 as preservatives.

The Calibration Curve is coded with blue alimentary dye.

Important Note: Even if plasma has been chemically inactivated, handle this component as potentially infectious.

# 3. Wash buffer concentrate: WASHBUF 20X

1x60ml/bottle 20x concentrated solution. Once diluted, the wash solution contains 10 mM phosphate buffer pH 7.0+/-0.2, 0.05% Tween 20 and 0.045% ProClin 300.

# 4. Enzyme conjugate : CONJ

1x16ml/vial. Ready to use and red colour coded. It contains Horseradish peroxidase conjugated polyclonal antibodies to human IgM, 5% BSA, 10 mM Tris buffer pH 6.8+/-0.1, 0.045% ProClin 300. and 0.02% gentamicine sulphate as preservatives.

#### 5. Chromogen/Substrate: SUBS TMB

1x16ml/vial. It contains 50  $\overline{\text{mM}}$  citrate-phosphate buffer pH 3.5-3.8, 4% dimethylsulphoxide, 0.03% tetra-methyl-benzidine (or TMB) and 0.02% hydrogen peroxide (or H<sub>2</sub>O<sub>2</sub>).

Note: To be stored protected from light as sensitive to strong illumination.

# 6. Sulphuric Acid: H2SO4 0.3 M

1x15ml/viallt contains 0.3 M H<sub>2</sub>SO<sub>4</sub> solution.

Attention: Irritant (H315, H319; P280, P302+P352, P332+P313, P305+P351+P338, P337+P313, P362+P363).

# 7. Specimen Diluent: DILSPE

2x60ml/vial. It contains 2% casein, 10 mM Na-citrate buffer pH 6.0 +/-0.1, 0.2% Tween 20, 0.09% Na-azide and 0.045% ProClin 300 as preservatives. To be used to dilute the sample.

# 8. Neutralizing Reagent: SOLN NEUT

1x8ml/vial. It contains goat anti hlgG, 2% casein, 10 mM Nacitrate buffer pH 6.0 +/-0.1, 0.09% Na-azide and 0.045% ProClin 300 as preservatives.

# 9. Plate sealing foils n°2

## 10. Package insert n°1

# E. MATERIALS REQUIRED BUT NOT PROVIDED

- Calibrated Micropipettes (1000, 100 and 10ul) and disposable plastic tips.
- 2. EIA grade water (bidistilled or deionised, charcoal treated to remove oxidizing chemicals used as disinfectants).
- 3. Timer with 60 minute range or higher.
- 4. Absorbent paper tissues.
- Calibrated ELISA microplate thermostatic incubator (dry or wet) set at +37°C (+/-0.5°C tolerance).
- Calibrated ELISA microwell reader with 450nm (reading) and with 620-630nm (blanking) filters.
- 7. Calibrated ELISA microplate washer.
- Vortex or similar mixing tools.

# F. WARNINGS AND PRECAUTIONS

- 1. The kit has to be used by skilled and properly trained technical personnel only, under the supervision of a medical doctor responsible of the laboratory.
- 2. All the personnel involved in performing the assay have to wear protective laboratory clothes, talc-free gloves and glasses. The use of any sharp (needles) or cutting (blades) devices should be avoided. All the personnel involved should be trained in biosafety procedures, as recommended by the Center for Disease Control, Atlanta, U.S. and reported in the National Institute of Health's publication: "Biosafety in Microbiological and Biomedical Laboratories", ed. 1984.

Doc.: INS CVM.CE Page 3 of 8 Rev.: 2 Date: 2019/11

- 3. All the personnel involved in sample handling should be vaccinated for HBV and HAV, for which vaccines are available, safe and effective.
- 4. The laboratory environment should be controlled so as to avoid contaminants such as dust or air-born microbial agents, when opening kit vials and microplates and when performing the test. Protect the Chromogen/Substrate (or TMB) from strong light and avoid vibration of the bench surface where the test is undertaken.
- 5. Upon receipt, store the kit at 2..8°C into a temperature controlled refrigerator or cold room.
- 6. Do not interchange components between different lots of the kits. It is recommended that components between two kits of the same lot should not also be interchanged.
- 7. Check that the reagents are clear and do not contain visible heavy particles or aggregates. If not, advise the laboratory supervisor to initiate the necessary procedures for kit replacement.
- 8. Avoid cross-contamination between serum/plasma samples by using disposable tips and changing them after each sample. Do not reuse disposable tips.
- 9. Avoid cross-contamination between kit reagents by using disposable tips and changing them between the use of each one. Do not reuse disposable tips.
- 10. Do not use the kit after the expiration date stated on the external container and internal (vials) labels. A study conducted on an opened kit did not pointed out any relevant loss of activity up to six 6 uses of the device and up to 6 months.
- 11. Treat all specimens as potentially infective. All human serum specimens should be handled at Biosafety Level 2, as recommended by the Center for Disease Control, Atlanta, U.S. in compliance with what reported in the Institutes of Health's publication: "Biosafety in Microbiological and Biomedical Laboratories", ed. 1984.
- 12. The use of disposable plastic-ware is recommended in the preparation of the liquid components or in transferring components into automated workstations, in order to avoid cross contamination.
- 13. Waste produced during the use of the kit has to be discarded in compliance with national directives and laws concerning laboratory waste of chemical and biological substances. In particular, liquid waste generated from the washing procedure, from residuals of controls/calibrators and from samples has to be treated as potentially infective material and inactivated before waste. Suggested procedures of inactivation are treatment with a 10% final concentration of household bleach for 16-18 hrs or heat inactivation by autoclave at 121°C for 20 min.
- 14. Accidental spills from samples and operations have to be adsorbed with paper tissues soaked with household bleach and then with water. Tissues should then be discarded in proper containers designated for laboratory/hospital waste.
- 15. The Sulphuric Acid is an irritant. In case of spills, wash the surface with plenty of water .
- 16. Other waste materials generated from the use of the kit (example: tips used for samples and controls/calibrators, used microplates) should be handled as potentially infective and disposed according to national directives and laws concerning laboratory wastes.

#### G. SPECIMEN: PREPARATION AND WARNINGS

- 1. Blood is drawn aseptically by venipuncture and plasma or serum is prepared using standard techniques of preparation of samples for clinical laboratory analysis. No influence has been observed in the preparation of the sample with citrate, EDTA and heparin.
- 2. Samples have to be clearly identified with codes or names in order to avoid misinterpretation of results. Bar code labeling and electronic reading is strongly recommended.
- 3. Haemolysed ("red") and visibly hyperlipemic ("milky") samples have to be discarded as they could generate false results. Samples containing residues of fibrin or heavy particles or

- microbial filaments and bodies should be discarded as they could give rise to false results.
- 4. Sera and plasma can be stored at +2°...+8°C in primary collection tubes for up to five days after collection.

Do not freeze primary tubes of collection. For longer storage periods, sera and plasma samples, carefully removed from the primary collection tube, can be stored frozen at -20°C for several months. Any frozen samples should not be frozen/thawed more than once as this may generate particles that could affect the test result.

5. If particles are present, centrifuge at 2.000 rpm for 20 min or filter using 0.2-0.8u filters to clean up the sample for testing.

#### H. PREPARATION OF COMPONENTS AND WARNINGS

#### Microplate:

Allow the microplate to reach room temperature (about 1 hr) before opening the container. Check that the desiccant is not turned to dark green, indicating a defect of storing.

In this case call Dia.Pro's customer service.

Unused strips have to be placed back into the aluminium pouch, in presence of desiccant supplied, firmly zipped and stored at +2°..8°C. When opened the first time, residual strips are stable till the indicator of humidity inside the desiccant bag turns from yellow to green.

#### **Calibration Curve**

Ready to use components. Mix carefully on vortex before use.

#### Wash buffer concentrate:

The whole content of the concentrated solution has to be diluted 20x with bidistilled water and mixed gently end-over-end before use. During preparation avoid foaming as the presence of bubbles could impact on the efficiency of the washing cycles. **Note:** Once diluted, the wash solution is stable for 1 week at

+2..8° C.

# Enzyme conjugate:

Ready to use. Mix well on vortex before use.

Be careful not to contaminate the liquid with oxidizing chemicals, air-driven dust or microbes.

If this component has to be transferred use only plastic, possibly sterile disposable containers.

## Chromogen/Substrate:

Ready to use. Mix well on vortex before use.

Be careful not to contaminate the liquid with oxidizing chemicals, air-driven dust or microbes.

Do not expose to strong illumination, oxidizing agents and metallic surfaces.

If this component has to be transferred use only plastic, possibly sterile disposable container

# Sample Diluent

Ready to use component. Mix carefully on vortex before use.

# Neutraling Reagent

Ready to use component. Mix carefully on vortex before use.

# Sulphuric Acid:

Ready to use. Mix well on vortex before use. Attention: Irritant (H315, H319; P280, P302+P352, P332+P313, P305+P351+P338, P337+P313, P362+P363). Doc.: INS CVM.CE Page 4 of 8 Rev.: 2 Date: 2019/11

# Warning H statements:

H315 - Causes skin irritation.

H319 - Causes serious eye irritation.

# Precautionary **P statements**:

**P280** – Wear protective gloves/protective clothing/eye protection/face protection.

P302 + P352 - IF ON SKIN: Wash with plenty of soap and water.

P332 + P313 - If skin irritation occurs: Get medical advice/attention.

P305 + P351 + P338 – IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.

P337 + P313 - If eye irritation persists: Get medical advice/attention.

P362 + P363 - Take off contaminated clothing and wash it before reuse.

# I. INSTRUMENTS AND TOOLS USED IN COMBINATION WITH THE KIT

- Micropipettes have to be calibrated to deliver the correct volume required by the assay and must be submitted to regular decontamination (household alcohol, 10% solution of bleach, hospital grade disinfectants) of those parts that could accidentally come in contact with the sample. They should also be regularly maintained in order to show a precision of 1% and a trueness of +/-2%. Decontamination of spills or residues of kit components should also be carried out regularly.
- The ELISA incubator has to be set at +37°C (tolerance of +/-0.5°C) and regularly checked to ensure the correct temperature is maintained. Both dry incubators and water baths are suitable for the incubations, provided that the instrument is validated for the incubation of ELISA tests.
- 3. The ELISA washer is extremely important to the overall performances of the assay. The washer must be carefully validated in advance, checked for the delivery of the right dispensation volume and regularly submitted to maintenance according to the manufacturer's instructions for use. In particular the washer, at the end of the daily workload, has to be extensively cleaned out of salts with deionized water. Before use, the washer has to be extensively primed with the diluted Washing Solution.

The instrument weekly has to be submitted to decontamination according to its manual (NaOH 0.1 M decontamination suggested).

5 washing cycles (aspiration + dispensation of 350ul/well of washing solution + 20 sec soaking = 1 cycle) are sufficient to ensure the assay with the declared performances. If soaking is not possible add one more cycle of washing.

An incorrect washing cycle or salt-blocked needles are the major cause of false positive reactions.

- 4. Incubation times have a tolerance of ±5%.
- 5. The ELISA microplate reader has to be equipped with a reading filter of 450nm and with a second filter of 620-630nm, mandatory for blanking purposes. Its standard performances should be (a) bandwidth ≤ 10 nm; (b) absorbance range from 0 to ≥ 2.0; (c) linearity to ≥ 2.0; repeatability ≥ 1%. Blanking is carried out on the well identified in the section "Assay Procedure". The optical system of the reader has to be calibrated regularly to ensure that the correct optical density is measured. It should be regularly maintained according to the manufacturer 's instructions.
- 6. When using an ELISA automated workstation, all critical steps (dispensation, incubation, washing, reading, data handling) have to be carefully set, calibrated, controlled and regularly serviced in order to match the values reported in the section "Internal Quality Control". The assay protocol has to be installed in the operating system of the unit and

validated as for the washer and the reader. In addition, the liquid handling part of the station (dispensation and washing) has to be validated and correctly set. Particular attention must be paid to avoid carry over by the needles used for dispensing and for washing. This must be studied and controlled to minimize the possibility of contamination of adjacent wells. The use of ELISA automated work stations is recommended when the number of samples to be tested exceed 20-30 units per run.

7. Dia.Pro's customer service offers support to the user in the setting and checking of instruments used in combination with the kit, in order to assure compliance with the requirements described. Support is also provided for the installation of new instruments to be used with the kit.

# L. PRE ASSAY CONTROLS AND OPERATIONS

- 1. Check the expiration date of the kit printed on the external label (primary container). Do not use if expired.
- Check that the liquid components are not contaminated by visible particles or aggregates.
- Check that the Chromogen/Substrate is colourless or pale blue by aspirating a small volume of it with a sterile plastic pipette.
- Check that no breakage occurred in transportation and no spillage of liquid is present inside the box (primary container). Check that the aluminium pouch, containing the microplate, is not punctured or damaged.
- 5. Dilute all the content of the 20x concentrated Wash Solution as described above.
- Allow all the other components to reach room temperature (about 1 hr) and then mix gently on vortex all liquid reagents.
- Set the ELISA incubator at +37°C and prepare the ELISA washer by priming with the diluted washing solution, according to the manufacturers instructions. Set the right number of washing cycles as reported in the specific section.
- Check that the ELISA reader is turned on or ensure it will be turned on at least 20 minutes before reading.
- 9. If using an automated work station, turn on, check settings and be sure to use the right assay protocol.
- 10. Check that the micropipettes are set to the required volume.
- 11. Check that all the other equipment is available and ready to use.
- 12. In case of problems, do not proceed further with the test and advise the supervisor.

# M. ASSAY PROCEDURE

The assay has to be carried out according to what reported below, taking care to maintain the same incubation time for all the samples in testing.

Two methods of analysis are possible, as described below:

# M.1 QUANTITATIVE ASSAY

- Place the required number of strips in the plastic holder and carefully identify the wells for calibrators and samples.
- Dilute samples 1:101 dispensing 1 ml Sample Diluent into a disposable tube and then 10 ul sample; mix on vortex before use. Do not dilute the Calibrators as they are ready-to-use.
- 3. Leave the A1+B1 wells empty for blanking purposes.
- Dispense 50 µl Neutralizing Reagent in all the wells, except A1+B1 wells used for blanking operations and the wells used for the Calibration Curve.

**Important note:** The Neutralizing Reagent is able to block false positive reactions due to RF. Positive samples in internal QC panels might be detected negative if such samples were tested positive with an IVD that does not carry out any RF blocking reaction.

Doc.: INS CVM.CE | Page | 5 of 8 | Rev.: 2 | Date: 2019/11

- In the identified positions pipette 100 µl of the Calibrators in duplicate followed by 100 µl of diluted samples. Check that Calibrators and samples have been correctly added.
- 6. Incubate the microplate for 60 min at +37°C.

**Important note:** Strips have to be sealed with the adhesive sealing foil, only when the test is performed manually. Do not cover strips when using ELISA automatic instruments.

- When the first incubation is finished, wash the microwells as previously described (section I.3)
- In all the wells, except A1+B1, pipette 100 µI Enzyme Conjugate. Incubate the microplate for 60 min at +37°C.

**Important note:** Be careful not to touch the plastic inner surface of the well with the tip filled with the Enzyme Conjugate. Contamination might occur.

- When the second incubation is finished, wash the microwells as previously described (section I.3)
- Pipette 100 µl Chromogen/Substrate into all the wells, A1+B1 included.

Important note: Do not expose to strong direct light. as a high background might be generated.

- 11. Incubate the microplate protected from light at room temperature (18-24°C) for 20 minutes. Wells dispensed with positive samples and with positive calibrators will turn from clear to blue.
- 12. Pipette 100 µl Sulphuric Acid into all the wells using the same pipetting sequence as in step 10 to block the enzymatic reaction. Addition of the stop solution will turn the positive calibrators and the positive samples from blue to yellow.
- 13. Measure the color intensity of the solution in each well, as described in section I.5 using a 450nm filter (reading) and a 620-630nm filter (background subtraction, mandatory), blanking the instrument on A1 or B1 or both.

# M.2 QUALITATIVE ASSAY

- 1. Place the required number of strips in the plastic holder and carefully identify the wells for calibrators and samples.
- Dilute samples 1:101 dispensing 1 ml Sample Diluent into a disposable tube and then 10 ul sample; mix on vortex before use. Do not dilute the Calibrators as they are ready-to-use.
- 3. Leave the A1 well empty for blanking purposes.
- Dispense 50 µl Neutralizing Reagent in all the wells, except A1 well used for blanking operations and the wells used for the Calibrators.
- Then pipette 100 μl of Calibrator 0 arbU/ml in duplicate, 100 μl of Calibrator 10 arbU/ml in triplicate and finally 100 μl of diluted samples. Check that Calibrators and samples have been correctly added.
- Incubate the microplate for 60 min at +37°C.

**Important note:** Strips have to be sealed with the adhesive sealing foil, only when the test is performed manually. Do not cover strips when using ELISA automatic instruments.

- When the first incubation is finished, wash the microwells as previously described (section I.3)
- In all the wells, except A1, pipette 100 µI Enzyme Conjugate. Incubate the microplate for 60 min at +37°C.

**Important note:** Be careful not to touch the plastic inner surface of the well with the tip filled with the Enzyme Conjugate. Contamination might occur.

9. When the second incubation is finished, wash the microwells as previously described (section I.3)

 Pipette then 100 μl Chromogen/Substrate into all the wells, A1 included.

Important note: Do not expose to strong direct light. as a high background might be generated.

- 11. Incubate the microplate protected from light at room temperature (18-24°C) for 20 minutes. Wells dispensed with positive samples and with positive calibrators will turn from clear to blue.
- 12. Pipette 100 µl Sulphuric Acid into all the wells using the same pipetting sequence as in step 10 to block the enzymatic reaction. Addition of the stop solution will turn the positive calibrators and the positive samples from blue to yellow.
- 13. Measure the color intensity of the solution in each well, as described in section I.5 using a 450nm filter (reading) and a 620-630nm filter (background subtraction, mandatory), blanking the instrument on A1.

#### General Important notes:

- Ensure that no finger prints are present on the bottom of the microwell before reading. Finger prints could generate false positive results on reading.
- Reading has to be carried out just after the addition of the Stop Solution and anyway not any longer than 20 minutes after its addition. Some self oxidation of the TMB chromogen can occur leading to high background.

#### N. ASSAY SCHEME

Method	Operations			
1110111011				
Neutralizing Reagent	50 μl			
Calibrators (no SOLN NEUT !)	100 µl			
Samples diluted 1:101	100 µl			
1 <sup>st</sup> incubation	60 min			
Temperature	+37°C			
Wash step	n° 5 cycles with 20" of			
	soaking			
	OR			
	n° 6 cycles without soaking			
Enzyme conjugate	100 µl			
2 <sup>nd</sup> incubation	60 min			
Temperature	+37°C			
Wash step	n° 5 cycles with 20" of			
	soaking			
	OR			
	n° 6 cycles without soaking			
TMB/H2O2	100 μΙ			
3 <sup>rd</sup> incubation	20 min			
Temperature	r.t.			
Sulphuric Acid	100 ul			
Reading OD	450nm / 620-630nm			

An example of dispensation scheme in quantitative assays is reported below:

# Microplate

	1	2	3	4	5	6	7	8	9	10	11	12
Α	BLK	CAL4	S3									
В	BLK	CAL4	S4									
С	CAL1	CAL5										
D	CAL1	CAL5	S6									
Е	CAL2	CAL6	S7									
F	CAL2	CAL6	S8									
G	CAL3	S1	S9									
Н	CAL3	S2	S10									

Legenda: BLK = Blank // CAL = Calibrators // S = Sample
An example of dispensation scheme in qualitative assays is reported below:

Dog.	INS CVM.CE	Dogo	6 of 9	Day 2	Date: 2019/11
D0C.:	INS CVIVI.CE	Page	6 of 8	Rev.: 2	Date: 2019/11

#### Microplate

	1	2	3	4	5	6	7	8	9	10	11	12
Α	BLK	S3										
В	CAL1	S4										
С	CAL1	S5										
D	CAL2	S6										
Е	CAL2	S7										
F	CAL2	S8										
G	S1	S9										
Н	S2	S10										

Legenda: BLK = Blank // CAL = Calibrators // CS = Control Serum // S = Sample

## O. INTERNAL QUALITY CONTROL

A validation check is carried out any time the kit is used in order to verify whether the performances of the assay are as qualified. Control that the following data are matched:

Parameter	Requirements
Blank well	< 0.100 OD450nm
Calibrator 0 arbU/ml	< 0.200 OD450nm after blanking
Calibrator 10 arbU/ml	OD450nm > OD450nm CAL 0 arbU/ml + 0.100
Calibrator 250 arbU/ml	3.500 > OD450nm > 2.000

If the results of the test match the requirements stated above, proceed to the next section.

If they do not, do not proceed any further and perform the following checks:

Problem	Check
Blank well > 0.100 OD450nm	that the Chromogen/Substrate solution has not become contaminated during the assay
Calibrator 0 arbU/ml > 0.200 OD450nm after blanking	1. that the washing procedure and the washer settings are as validated in the pre qualification study; 2. that the proper washing solution has been used and the washer has been primed with it before use; 3. that no mistake has been done in the assay procedure (dispensation of positive calibrators instead of Cal 0 arbU/ml); 4. that no contamination of the Cal 0 arbU/ml, or of the wells where this was dispensed, has occurred due to positive samples, to spills or to the enzyme conjugate; 5. that micropipettes have not become contaminated with positive samples or with the enzyme conjugate 6. that the washer needles are not blocked or partially obstructed.

Calibrator	1. that the procedure has been correctly							
10 arbU/ml	performed;							
	2. that no mistake has occurred during its							
< CAL 0 + 0.100	distribution;							
	3. that the washing procedure and the washer							
	settings are as validated in the pre qualification							
	study; 4. that no external contamination of the calibrator has occurred.							
A !!! .								
Calibrator	1. that the procedure has been correctly							
250 arbU/ml	performed;							
< 2.000 OD450nm	2. that no mistake has occurred during the							
	distribution of the calibrator;  3. that the washing procedure and the washer							
	3. that the washing procedure and the washer							
	settings are as validated in the pre qualification							
	study;							
	4. that no external contamination of the							
	calibrator has occurred.							
Calibrator	1. that the washing procedure and the washer							
250 arbU/ml	settings are as validated in the pre qualification							
> 3.500 OD450nm	study:							
after blanking	2. that the proper washing solution has been							
3	used and the washer has been primed with it							
	before use;							
	3. that no mistake has been done in the assay							
	procedure:							
	4. that no contamination of the Cal 250 arbU/ml.							
	or of the wells where this was dispensed, has							
	occurred due to positive samples, to spills or to							
	the enzyme conjugate;							
	5. that micropipettes have not become							
	contaminated with positive samples or with the							
	enzyme conjugate							
	6. that the washer needles are not blocked or							
	partially obstructed.							

If any of the above problems has occurred, report the problem to the supervisor for further actions.

#### P. RESULTS

If the test turns out to be valid, interpretation of results is carried out in the **quantitative assay** from the mean OD450nm value of the Calibration Curve elaborated with an appropriate curve fitting system (suggested: 4 parameters).

In the **qualitative assay** interpretation of results is done on the mean OD450nm value of the Calibrator 10 arbU/ml (or CAL 2) by means of the following formulation:

# Mean OD450nm CAL 2 = cut-off (Co)

**Important note**: When the calculation of results is performed by the operating system of an ELISA automated work station, ensure that the proper formulation is used to generate the correct interpretation of results.

# Q. INTERPRETATION OF RESULTS

# **Q.1 QUANTITATIVE ASSAY**

Concentrations in arbU/ml are obtained elaborating OD450nm of samples on the fitted calibration curve.

The concentration of IgM is from Literature correlated proportionally with the liver damage produced by antibodies to HCV upon virus replication in hepatocites.

A decrease in IgM concentration upon pharmacological treatment is usually clinically acknowledged as a sign of recovery and therapeutic efficacy.

Doc.:	INS CVM.CE	Page	7 of 8	Rev.: 2	Date: 2019/11
DUC	II VO C V IVI.CE	1 agc	/ 01 0	IXC V Z	Date. 2019/11

#### Q.2 QUALITATIVE ASSAY

Test results are interpreted as a ratio of the sample OD450nm value (S) and the cut-off value (Co), or S/Co, according to the following table:

S/Co	Interpretation
< 1.0	Negative
> 1.0	Positive

A negative result indicates that the patient has not developed IqM antibodies to HCV.

A positive result is indicative of an ongoing HCV active infection.

#### Important notes:

- Interpretation of results should be done under the supervision of the laboratory supervisor to reduce the risk of judgment errors and misinterpretations.
- When test results are transmitted from the laboratory to another facility, attention must be paid to avoid erroneous data transfer.
- Diagnosis has to be done and released to the patient by a suitably qualified medical doctor.
- The results of this ELISA assay should be anyway implemented with other diagnostic and clinical tests.

An example of calculation is reported below.

The following data must not be used instead or real figures obtained by the user.

CAL 1: 0.060 – 0.080 OD450nm Mean Value: 0.070 OD450nm Lower than 0.200 – Accepted

CAL 2: 0.200 - 0.220 - 0.021 OD450nm

Mean Value: 0.210 OD450nm Higher than CAL1+0.100 = accepted

Cut-Off or Co = 0.210

 Sample 1:
 0.080 OD450nm

 Sample 2:
 1.800 OD450nm

 Sample 1
 S/Co < 1.0 = negative</td>

 Sample 2
 S/Co > 1.0 = positive

## R. PERFORMANCE CHARACTERISTICS

Evaluation of Performances has been conducted on selected panels carried out in a clinical external center and internally.

#### 1. Limit of detection

No international standard for HCV IgM Antibody detection has been defined so far by the European Community.

In its absence, an Internal Gold Standard (or IGS), derived from a patient with an history of chronic HCV infection, has been defined in order to provide the device with a constant and excellent sensitivity.

# 2. Diagnostic Sensitivity and Specificity:

The diagnostic performances were evaluated in a study conducted in an external clinical center, with excellent experience in the diagnosis of infectious diseases and HCV.

The Diagnostic Sensitivity was studied on about 200 samples, pre-tested positive with an analytical system developed in house by the clinical laboratory where the study was conducted. Positive samples were collected from patients with a clinical history of HCV infection (acute and chronic).

In addition some Seroconversion Panels, purchased from Boston Biomedica Inc., USA, were examined.

The diagnostic specificity was determined on panels of more than 300 negative samples from normal individuals and blood donors, classified negative for anti HCV antibodies with the reference kit in use in the laboratory, including potentially interfering specimens.

A panel of potentially interfering samples (RF+, hemolised, lipemic, etc.) was also examined. No interference was observed on the samples examined.

Both plasma, derived with different standard techniques of preparation (citrate, EDTA and heparin), and sera have been used to determine the specificity. No false reactivity due to the method of specimen preparation has been observed.

Frozen specimens have also been tested to check whether samples freezing interferes with the performance of the test. No interference was observed on clean and particle free samples.

The Performance Evaluation provided the following values :

Sensitivity	> 98 %
Specificity	> 98 %

#### 3. Reproducibility:

It has been calculated on two samples examined in replicates in different runs. Results are reported below summarized in a table:

Average values N = 48	Calibrator 2 10 arbU/ml	Calibrator5 100 arbU/ml
OD450nm	0.241	1.632
Std.Deviation	0.027	0.113
CV %	11.3	6.9

# S. LIMITATIONS

False positivity has been assessed on less than 2% of the normal population, mostly due to high titers of RF.

Frozen samples containing fibrin particles or aggregates may generate false positive results.

D	INS CVM.CE	D	1 -£ 0	D 2	Date: 2019/11
DOC.:	LINS CVIVICE	Page	Lot 8	Rev.: 2	Date: /UT9/11

#### **BIBLIOGRAPHY**

- 1. Krasavtsev EL, Zhavoronok SV, Mitsura VM, Demchilo AP. Zh Mikrobiol Epidemiol Immunobiol. 2006 Mar-Apr;(2):57-61
- 2. Papatheodoridis GV, Delladetsima JK, Katsoulidou A, Sypsa V, Albrecht M, Michel G, Hatzakis A, Tassopoulos NC. J Hepatol. 1997 Jul;27(1):36-41.
- 3. Martinelli AL, Brown D, Braun HB, Michel G, Dusheiko GM. J Hepatol. 1996 Jan;24(1):21-6.
- **4**. Pawlotsky JM, Darthuy F, Remire J, Pellet C, Udin L, Stuyver L, Roudot-Thoraval F, Duvoux C, Douvin C, Mallat A, et al. J Med Virol. 1995 Nov;47(3):285-91.
- **5**. Stransky J, Honzakova E, Vandasova J, Horejsova M, Kyncl J, Nemecek V, Horak J. Acta Virol. 1996 Apr;40(2):61-5.
- **6.** Nikolaeva LI, Blokhina NP, Tsurikova NN, Voronkova NV, Miminoshvili MI, Braginsky DM, Yastrebova ON, Booynitskaya OB, Isaeva OV, Michailov MI, Archakov AI. Gut. 2000 Nov;47(5):698-702.
- **7.** Bizollon T, Ahmed SN, Guichard S, Chevallier P, Adham M, Ducerf C, Baulieux J, Trepo C. J Med Virol. 1998 Nov;56(3):224-9.
- 8. Tran A, Yang G, Dreyfus G, Rouquie P, Durant J, Rampal A, Rampal P, Benzaken S. Am J Gastroenterol. 1997 Oct;92(10):1835-8.

All the IVD Products manufactured by the company are under the control of a certified Quality Management System approved by an EC Notified Body. Each lot is submitted to a quality control and released into the market only if conforming with the EC technical specifications and acceptance criteria.

Manufacturer:

Dia.Pro Diagnostic Bioprobes S.r.l. Via G. Carducci n° 27 – Sesto San Giovanni (MI) – Italy

